These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 29263444)

  • 1. Inflammation and CVD in 2017: From clonal haematopoiesis to the CANTOS trial.
    Swirski FK
    Nat Rev Cardiol; 2018 Feb; 15(2):79-80. PubMed ID: 29263444
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk: JACC Review Topic of the Week.
    Ridker PM
    J Am Coll Cardiol; 2018 Dec; 72(25):3320-3331. PubMed ID: 30415883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for cardiovascular disease.
    Lutgens E; Atzler D; Döring Y; Duchene J; Steffens S; Weber C
    Eur Heart J; 2019 Dec; 40(48):3937-3946. PubMed ID: 31121017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammation and Atherosclerosis: The End of a Controversy.
    Hansson GK
    Circulation; 2017 Nov; 136(20):1875-1877. PubMed ID: 28916641
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical approach to the inflammatory etiology of cardiovascular diseases.
    Ruscica M; Corsini A; Ferri N; Banach M; Sirtori CR
    Pharmacol Res; 2020 Sep; 159():104916. PubMed ID: 32445957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disordered haematopoiesis and cardiovascular disease: a focus on myelopoiesis.
    Dragoljevic D; Westerterp M; Veiga CB; Nagareddy P; Murphy AJ
    Clin Sci (Lond); 2018 Sep; 132(17):1889-1899. PubMed ID: 30185612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Body fat and metabolic age as indicators of inflammation and cardiovascular risk.
    Garcia-Rubira JC; Cano-Garcia FJ; Bullon B; Seoane T; Villar PV; Cordero MD; Bullon P
    Eur J Prev Cardiol; 2018 Feb; 25(3):233-234. PubMed ID: 29164910
    [No Abstract]   [Full Text] [Related]  

  • 8. Colchicine in coronary disease: another renaissance of an ancient drug.
    Fiolet ATL; Thompson PL; Mosterd A
    Cardiovasc Res; 2021 Jan; 117(1):e4-e6. PubMed ID: 33426561
    [No Abstract]   [Full Text] [Related]  

  • 9. Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice.
    Tuñón J; Bäck M; Badimón L; Bochaton-Piallat ML; Cariou B; Daemen MJ; Egido J; Evans PC; Francis SE; Ketelhuth DF; Lutgens E; Matter CM; Monaco C; Steffens S; Stroes E; Vindis C; Weber C; Hoefer IE;
    Eur J Prev Cardiol; 2018 Jun; 25(9):948-955. PubMed ID: 29759006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the immune response in atherosclerosis: It's time for clinical trials!
    Joffre J; Ait-Oufella H
    Arch Cardiovasc Dis; 2017 Dec; 110(12):643-645. PubMed ID: 29051009
    [No Abstract]   [Full Text] [Related]  

  • 11. The Utility of Anti-Inflammatory Agents in Cardiovascular Disease: A Novel Perspective on the Treatment of Atherosclerosis.
    Kottoor SJ; Arora RR
    J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):483-493. PubMed ID: 29783850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapies and outcomes data: the inflammatory hypothesis matures.
    Sharan L; Krasuski RA
    Curr Opin Lipidol; 2018 Feb; 29(1):56-57. PubMed ID: 29298276
    [No Abstract]   [Full Text] [Related]  

  • 13. The Inter-Relationship of Platelets with Interleukin-1β-Mediated Inflammation in Humans.
    Tunjungputri RN; Li Y; de Groot PG; Dinarello CA; Smeekens SP; Jaeger M; Doppenberg-Oosting M; Cruijsen M; Lemmers H; Toenhake-Dijkstra H; Aguirre-Gamboa R; Kumar V; Wijmenga C; Joosten LAB; Netea MG; van der Ven A; de Mast Q
    Thromb Haemost; 2018 Dec; 118(12):2112-2125. PubMed ID: 30453346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NOVEL MECHANISMS AND ANTI-INFLAMMATORY STRATEGIES TO REDUCE CARDIOVASCULAR RISK IN HUMAN IMMUNODEFICIENCY VIRUS.
    Grinspoon S
    Trans Am Clin Climatol Assoc; 2018; 129():140-154. PubMed ID: 30166708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammation modulation and cardiovascular disease prevention.
    Awan Z; Genest J
    Eur J Prev Cardiol; 2015 Jun; 22(6):719-33. PubMed ID: 24711609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammation: a common contributor to cancer, aging, and cardiovascular diseases-expanding the concept of cardio-oncology.
    Libby P; Kobold S
    Cardiovasc Res; 2019 Apr; 115(5):824-829. PubMed ID: 30830168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CANTOS - is selective targeting of inflammation in atherosclerosis enough?
    Misra DP; Agarwal V
    J R Coll Physicians Edinb; 2018 Sep; 48(3):246-247. PubMed ID: 30191914
    [No Abstract]   [Full Text] [Related]  

  • 18. Inflammation and coronary artery disease: from pathophysiology to Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).
    Ali M; Girgis S; Hassan A; Rudick S; Becker RC
    Coron Artery Dis; 2018 Aug; 29(5):429-437. PubMed ID: 29652673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelial Cells: From Dysfunction Mechanism to Pharmacological Effect in Cardiovascular Disease.
    Haybar H; Shahrabi S; Rezaeeyan H; Shirzad R; Saki N
    Cardiovasc Toxicol; 2019 Feb; 19(1):13-22. PubMed ID: 30506414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural Moieties as Anti-Inflammatory Agents-Recent Patents.
    Tuli HS; Sharma A; Thakur A
    Recent Pat Inflamm Allergy Drug Discov; 2019; 13(2):83. PubMed ID: 31814544
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.